『ファルマシア』（日本薬学会会誌）5月号にて当社に関する記事が掲載されました
『ファルマシア』（日本薬学会会誌）5月号にて、当社の強みと挑戦をご紹介いただきました。特集「未来のがん治療」内の企画『日本ベンチャーの底力』で、「BROTHERS技術で切り拓く核酸医薬の未来」と題し、コア技術や
2025年5月14日
Menu
We stand up for novel and effective drugs
“because we see our patients fighting…”
当社の研究が国立研究開発法人日本医療研究開発機構（AMED）の研究費に採択されました
この度、当社の研究が、国立研究開発法人日本医療研究開発機構（AMED）の「令和6年度 次世代治療・診断実現のための創薬基盤技術開発事業（次世代送達技術を用いた医薬品研究開発）」に採択されましたことをご報告いたし
2025年4月23日
2025年2月10日
Founder’s Philosophy
Our company started with a consistent philosophy of our founder, Mariko Harada-Shiba, M.D., Ph.D., a medical doctor and a researcher; “to save patients we see by all means.” We are seeing nucleic acid-based therapeutic drugs as a panacea for various intractable and difficult-to-treat diseases.
Antisense drugs
Proteins are very fundamental and essential components of our bodies, whereas it is a fact that malfunction of them is also involved in many diseases. Protein information is stored in DNA and is extracted as messenger RNA (mRNA) when needed. A nucleic acid drug (called antisense) can bind to this mRNA and suppress the production of disease-related proteins. We believe that this method will lead to the treatment of many diseases for which there have been no effective drugs.
Technologies and
Pipelines
We have succeeded in creating a unique nucleic acid drug discovery platform by utilizing the excellent technologies built at the National Cerebral and Cardiovascular Center, as well as Osaka University, Nagasaki University, Tokushima Bunri University, and others.
Technologies
Pipeline
